Sleep Disorders

The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Michael J. Thorpy, MD.

While the relationship between sleep and cognition needs to be further studied, sleep-based interventions may be a future approach to help prevent cognitive decline.

The medical director of the Ohio State Sleep Medicine Institute detailed the progress made within the sleep disorder field in recent years and where it can turn to next.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center detailed the overall state of sleep care and the advantages the investigational FT218 brings to the growing pipeline.

Here's what is coming soon to NeurologyLive.

The task force assessed 6 total interventions, all of which received conditional recommendations aside from cognitive behavioral therapy for insomnia, which was strongly recommended.

Results from the START study of medication switching in narcolepsy were presented at the 2021 SLEEP Annual Meeting.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center discussed the formulaic background of FT218 and why it’s so effective in treating sleep disorders.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 11, 2021.

The FDA-approved agent demonstrated meaningful reduction in the frequency of cataplexy attacks in adults with narcolepsy, including patients with a high symptom burden.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why advanced practice clinicians should be utilized more in neurology settings.

Data presented at SLEEP 2021 also showed the treatment was associated with significant weight loss and reduction in BMI compared to placebo.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 4, 2021.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 28, 2021.

Six months after being discharged from the hospital for COVID-19, patients scored worse than average on 1 or more NeuroQoL scale components, which measured anxiety, sleep, fatigue, and depression.

In addition to focusing on healthy sleep habits, researchers reinforce empowering children and adolescents to navigate the “brave new world” of online and hybrid schooling influenced by the pandemic.

A 5-year, post-approval study of the remedē System confirmed results of the pivotal trial.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

The director of research at St. Luke’s Sleep Medicine and Research Center discussed the current treatment landscape for excessive daytime sleepiness and how solriamfetol plays a role.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 14, 2021.

The director of the sleep disorders center at Cleveland Clinic discussed the data on lower sodium oxybate presented at AAN 2021.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed the aim of his practice’s study.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.